Jaguar Health & Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguar’s Personalized, Premium Product f...
December 14 2017 - 10:09AM
Business Wire
Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products
pharmaceuticals company focused on developing and commercializing
novel, sustainably derived gastrointestinal products for both human
prescription use and animals on a global basis, announced today
that it has entered into a collaboration agreement (the Agreement)
with Seed Mena Businessmen Services LLC (SEED) for Equilevia™,
Jaguar’s non-prescription, personalized, premium product for total
gut health in equine athletes. Based in Dubai in the United Arab
Emirates (UAE), SEED is affiliated with Seed Group, a diversified
group of companies under the umbrella of The Private Office of His
Royal Highness Sheikh Saeed Bin Ahmed Al Maktoum establishing
strategic partnerships with multinational companies from around the
globe in an aim to leverage Seed Group’s network to support
potential business expansion in the MENA (Middle East and North
Africa) region.
Equilevia™ contains ingredients isolated and purified from the
medicinal Croton lechleri tree, which is sustainably harvested from
the rainforest. Equilevia™ acts locally in the gut. Gut health is
of critical importance in competitive horses, as conditions such as
ulcers can meaningfully impair equine athlete performance, and
colic can lead to the death of an otherwise healthy horse in a
matter of hours. According to a third-party 2005 study, as many as
55% of performance horses have both colonic and gastric ulcers, and
97% of performance horses have either a gastric (87%) or a colonic
(63%) ulcer.1
“In the Gulf economies, the traditional hobbies of local
populations have become widespread activities—and nowhere is this
more true than for horses, an age-old passion of the region’s
Bedouin tribes. The modernization of the competitive equine
industry in the UAE has mirrored the development of the nation, and
the country has become a global leader in horse racing, equine
endurance competitions, and other equine athletic activities,”
commented Mohammed Al Banna, Senior Director, International
Ventures at Seed Group. “We look forward to capitalizing on SEED’s
network and contacts in the private and public sector in the UAE as
part of our strategic partnership with Jaguar to drive improved gut
health management in these exquisite athletes through Equilevia™
awareness and sales in the region.”
In 2017, 7,399 horses and 1,437 “equine athletes” from the UAE
Equestrian & Racing Federation, which supervises the
organization of equestrian and racing activities in the UAE, are
registered with The International Federation for Equestrian Sports,
the international governing body of equestrian athletics.
Approximately 2,000 active endurance-racing horses and 87 racing
stables in the UAE were listed by the Emirates Equestrian
Federation in 2012.
“The need for a personalized, premium product for total gut
health in equine athletes was originally identified by the late Dr.
Mike Hauser—Jaguar’s former chief veterinarian and the former head
of the world-renowned Dubai Equine Hospital,” Lisa Conte, Jaguar's
president and CEO, stated. “Mike had an intimate understanding of
the training conditions and value of equine health in the UAE, and
he is frequently credited with being the primary force behind
bringing leading-edge equine medicine and surgery to the Middle
East. We’re very excited about a new potential approach for total
gut health in competitive horses—and about our new partnership with
SEED—and in the UAE region we plan to focus initial sales and
collaborative efforts on particular stables, tailored to the
particular equine husbandry practices of specific organizations and
even individual high-end equine athletes. The terms of the
Agreement reflect the financial impact we expect Equilevia™ to have
on Jaguar’s business, with potentially hundreds to thousands of
horses treated regularly to maintain wellness. We’re so pleased to
have entered a collaboration intended to supplement our commercial
human pharmaceutical business with a product designed for the most
venerable participants in the sport of kings.”
Jaguar has tested Equilevia™ for safety and wellness in both
racing horses and horses in training. The results of testing in
actively racing horses resulted in more top placements and greater
purses for horses given Equilevia™ than for horses on placebo, as
well as observations of improved equine “wellness.”
According to the terms of the Agreement, Jaguar will pay SEED an
ongoing percentage of revenue generated from any clients or
partners introduced to Jaguar by SEED, and the agreed-upon revenue
percentage increases after the first one-million dollars of
revenue.
About Jaguar Health, Inc.
Jaguar Health, Inc. is a natural-products pharmaceuticals
company focused on developing and commercializing novel,
sustainably derived gastrointestinal products for both human
prescription use and animals on a global basis. Our wholly-owned
subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and
commercializing proprietary human gastrointestinal pharmaceuticals
for the global marketplace from plants used traditionally in
rainforest areas. Our Mytesi® (crofelemer) product is approved by
the U.S. FDA for the symptomatic relief of noninfectious diarrhea
in adults with HIV/AIDS on antiretroviral therapy. Canalevia™ is
our lead animal prescription drug candidate, intended for treatment
of various forms of diarrhea in dogs. Equilevia™ is Jaguar’s
non-prescription product for total gut health in equine athletes.
Canalevia™ and Equilevia™ contain ingredients isolated and purified
from the Croton lechleri tree, which is sustainably harvested.
Neonorm™ Calf and Neonorm™ Foal are Jaguar’s lead non-prescription
animal products. Mytesi®, Canalevia™, Equilevia™ and Neonorm™ are
distinct products that act at the same last step in a physiological
pathway generally present in mammals.
For more information about Jaguar, please visit jaguar.health.
For more information about Napo, visit napopharma.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements.” These include statements regarding
the expectation that Jaguar and SEED will capitalize on SEED’s
network and contacts in the private and public sector in the UAE
and drive Equilevia™ awareness and sales in the region, a new
potential approach for total gut health in competitive horses, the
financial impact Jaguar expects Equilevia™ to have on the Company’s
business, with potentially hundreds to thousands of horses treated
regularly to maintain wellness, and planned, potential follow-on
indications for Mytesi®. In some cases, you can identify
forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms
or other similar expressions. The forward-looking statements in
this release are only predictions. Jaguar has based these
forward-looking statements largely on its current expectations and
projections about future events. These forward-looking statements
speak only as of the date of this release and are subject to a
number of risks, uncertainties and assumptions, some of which
cannot be predicted or quantified and some of which are beyond
Jaguar’s control. Except as required by applicable law, Jaguar does
not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise.
1Pellegrini FL. Results of a large-scale necroscopic study of
equine colonic ulcers. J Equine Vet Sci. 2005;25(3):113-117.
Jaguar-JAGX
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171214005874/en/
Jaguar Health, Inc.Peter Hodgephodge@jaguar.health
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Apr 2023 to Apr 2024